Navigation Links
Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
Date:9/17/2008

definite multiple sclerosis."

"As a leader in multiple sclerosis treatments, we are committed to providing new options that can further improve the course of the disease and the quality of life for people living with this disease," said Dr. Richard Douge, Executive Vice President, Global Marketing, Merck Serono. "The initiation of the ORACLE MS study further demonstrates our commitment to continue to build a solid portfolio of products for use in a broad multiple sclerosis patient population. We believe that our proprietary oral formulation of Cladribine has the potential to address an important unmet medical need at a critical time of disease development."

The ORACLE MS study is a randomized, double-blind, placebo-controlled, international trial. It will involve more than 600 patients considered at risk of developing MS due to a recently experienced isolated demyelinating event (e.g. optic neuritis, myelopathy or brainstem syndrome) and having MRI brain scans consistent with early signs of MS. Study participants will be randomized in one of the three arms of the study to receive one of two different dosage regimens of Cladribine tablets or matching placebo tablets (1:1:1 ratio).

Patients will be treated for a period of two years (96 weeks), or up to the time when they experience a second attack leading to a diagnosis of clinically definite MS, in which case they would be offered open-label treatment with Rebif(R) 44 mcg three times a week for a 96-week maintenance treatment period. Patients who do not convert to clinically definite MS within the initial 96-week period of the study will be eligible to enroll in a 96- week long-term follow-up treatment period. These maintenance and long-term follow-up periods of the study are intended to assess the effect of early treatment with Cladribine tablets on relapses and subsequent treatment response to disease-modifying therapy for relapsing-remitting MS and to evaluate the sustained effect of Cladribi
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
4. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
10. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
11. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Inc. (OTC Bulletin Board: HEWA) an online U.S. mail-order ... 12% per annum short term debt financing. The ... of $500,000, with accrued interest and principal repayable in ... interest and principal repayable in one year from its ... for any calendar month prior to December 15, 2010. ...
(Date:12/16/2009)... EuroPharma, Inc. signs exclusive multi-year ... of super absorbency BCM-95® curcumin and specialized ... The exclusive distribution territory for these clinically-studied ... channel and professional channel, which includes allopathic ... BCM-95® is a highly absorbable curcumin. ...
(Date:12/16/2009)... INDIANAPOLIS, Dec. 16 RealMed has ... Service in the 2009 Top 20 ... Services report. RealMed is a dynamic ... automated transactions processing between healthcare providers and ... independent research firm specializing in vendor performance ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 1President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 2President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 3ForteBio Launches Two Revolutionary High Throughput Label Free Instruments 3A The Octet 28R 29 RED384 and the Octet QK384 12733 1ForteBio Launches Two Revolutionary High Throughput Label Free Instruments 3A The Octet 28R 29 RED384 and the Octet QK384 12733 2ForteBio Launches Two Revolutionary High Throughput Label Free Instruments 3A The Octet 28R 29 RED384 and the Octet QK384 12733 3Obama Signs Tough New Anti Smoking Law 49671 1Obama Signs Tough New Anti Smoking Law 49671 2
(Date:12/17/2009)... -- CareFusion Corporation (NYSE: CFN ) announced ... mini-tender offer by TRC Capital Corporation (TRC) to purchase ... representing approximately 1.8 percent of the shares of common ... is 4.62 percent below the share closing price of ... full trading day prior to the offer. CareFusion also ...
(Date:12/17/2009)... elder care expert announces the release of her new book “Priceless ... is a contributing author and the primary compiler of stories for ... Now released in paperback, Priceless Caregiving can be ordered through ... ... St. Louis, MO (PRWEB) December 17, 2009 -- Valerie VanBooven RN ...
(Date:12/17/2009)... portrait of the nearly one-in-three American adults who serve as a ... ... 2009 -- The National Alliance on Mental Illness (NAMI) praises a ... a revealing portrait of the nearly one-in-three American adults who serve ... interviews with 1,480 caregivers chosen at random and offers a national ...
(Date:12/17/2009)... MediNiche provide alternative natural relief prior to considering drugs. ... ... 17, 2009 -- D-Psoria products are the first ... with severe skin conditions . Developed by Astrel ... MediNiche Pharmaceuticals, St. Louis, Missouri., , ,D-Psoria products ...
(Date:12/17/2009)... Healthcare Cost/Risk Analysis reports, activity measures and outcomes reporting to ... toward reduced claim costs and positive return on investment over ... ... Jacksonville, FL (PRWEB) December 17, 2009 -- ... in clinical/claims based cost risk analysis along with personalized nurse ...
Breaking Medicine News(10 mins):Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families 2Health News:Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families 3Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2
... study appearing online on February 8 in advance of ... of Clinical Investigation//, Daniel Weinberger and colleagues from the ... encodes DARPP-32 exhibits genetic variation. ,Several neurological ... are associated with changes in the brain that affect ...
... According to a study conducted by British researchers, breast fed ... fed counterparts//. This once again goes on to prove the ... conducted by Institute of Child Health in London among 262 ... In this group, 184 children have been bottle-fed with formula ...
... there is a fine line between genius and madness and this may ... Mental health workers have always been baffled by one of the most ... affect one in 100 persons and causes disordered ideas, beliefs, and experiences. ... 25 to 35. , Scientists working for U.S National ...
... to an article recently published in the journal Blood, ... risk of diabetes and hypertension. ,An allogeneic ... types of cancers, particularly leukemia and lymphoma. The process ... use of high-dose chemotherapy or total body irradiation. These ...
... Duke University Medical Center researchers have created// a three-dimensional ... physicians to repair damaged joints with the patient's own ... successful, the scaffold could be used in clinical trials ... graduate student in the Orthopedic Bioengineering Laboratory who designed ...
... Technology are one step closer to developing a ... most common sexually-transmitted disease, Chlamydia. ... a funding boost of more than $300,000 to ... developing a vaccine specifically targeting adolescent women. ...
Other Medicine News:Health News:Madness- the Genius Connection 2Health News:Allogeneic Stem Cell Transplants Linked With Risk for Diabetes and Hypertension 2Health News:Woven Cartilage 2Health News:Chlamydia Vaccine a Step Closer to Reality 2
... test device is intended for ... IgG and IgM antibodies to ... The test is used as ... of Dengue viral infection and ...
RapidStrep A test is a qualitative test that detects group A,streptococcal antigen. The test is a rapid, in vitro assay. It is,intended for professional use to help diagnose Strep A,infection i...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
Inquire...
Medicine Products: